- Home
- AARD vs RXST Comparison
AARD vs RXST Comparison
Compare AARD & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- RXST
- Stock Information
- Founded
- AARD 2017
- RXST 1997
- Country
- AARD United States
- RXST United States
- Employees
- AARD N/A
- RXST N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AARD Health Care
- RXST Health Care
- Exchange
- AARD Nasdaq
- RXST Nasdaq
- Market Cap
- AARD 277.9M
- RXST 307.3M
- IPO Year
- AARD 2025
- RXST 2021
- Fundamental
- Price
- AARD $11.22
- RXST $8.62
- Analyst Decision
- AARD Strong Buy
- RXST Hold
- Analyst Count
- AARD 7
- RXST 11
- Target Price
- AARD $31.43
- RXST $11.80
- AVG Volume (30 Days)
- AARD 151.9K
- RXST 661.1K
- Earning Date
- AARD 11-14-2025
- RXST 11-05-2025
- Dividend Yield
- AARD N/A
- RXST N/A
- EPS Growth
- AARD N/A
- RXST N/A
- EPS
- AARD N/A
- RXST N/A
- Revenue
- AARD N/A
- RXST $147,059,000.00
- Revenue This Year
- AARD N/A
- RXST N/A
- Revenue Next Year
- AARD N/A
- RXST $6.71
- P/E Ratio
- AARD N/A
- RXST N/A
- Revenue Growth
- AARD N/A
- RXST 27.68
- 52 Week Low
- AARD $4.88
- RXST $6.32
- 52 Week High
- AARD $19.58
- RXST $55.57
- Technical
- Relative Strength Index (RSI)
- AARD 39.08
- RXST 51.05
- Support Level
- AARD $10.65
- RXST $8.33
- Resistance Level
- AARD $17.94
- RXST $8.70
- Average True Range (ATR)
- AARD 0.95
- RXST 0.37
- MACD
- AARD -0.64
- RXST 0.08
- Stochastic Oscillator
- AARD 7.82
- RXST 81.54
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.